Deal comes as a Delaware judge is currently weighing whether to accept or reject plaintiffs' expert witness testimony in more than 70,000 other Zantac lawsuits still pending in that state.
Second time in the last month GlaxoSmithKline has reached a Zantac settlement agreement just before a case was set to go before a jury, privately resolving claims that the recalled heartburn drug caused cancer
Although GlaxoSmithKline has agreed to several Zantac settlements payouts in recent months, the drug maker indicates that it plans to continue defending against cancer lawsuits being pursued by former users of Zantac.
GlaxoSmithKline, Boehringer Ingelheim, Pfizer and other drug makers face more than 70,000 Zantac cancer lawsuits in Delaware state court, after a U.S. District Judge dimissed all claims filed in the federal court system in 2022.
Plaintiff indicates he suffered an Ozempic overdose after Giant pharmacy accidentally gave him four times the prescribed dosage of the diabetes drug.
The federal dismissal does not directly affect Zantac lawsuits filed in state courts nationwide, where cases are scheduled to go to trial throughout 2023
